Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia
View Full Paper
Ask AI
Bookmark
Share
Key result
Between 2016 and 2020, the proportion of fixed-dose combination products among all dispensed antihypertensives in Germany decreased from 15.4% to 10.9%, documenting underutilization of guideline recommendations.
Why the study?
The 2018 ESC/ESH guidelines recommend initial fixed-dose single-pill combination therapy for hypertension, but data on the implementation of these recommendations in clinical practice were scarce.
Population
Approximately 73.3 million subjects in Germany representing approximately 88% of the population
Comparison
Fixed-dose combination antihypertensive products vs all antihypertensive products over time
Design
Retrospective prescription database analysis
Authors
Discussion
Loading...
Member takes
Implication
Low SPC use persists in Germany despite 2018 guidelines; leaves open whether targeted interventions improve real-world adherence and BP control.
Study Design
Type
Observational (n=73,300,000)
Structured PICO
P
Population
A nationwide drug utilization analysis covering approximately 73.3 million statutorily insured subjects in Germany to evaluate the dispensing of antihypertensive fixed-dose combinations between 2016 and 2020.
E
Exposure
Fixed-dose combination (FDC) antihypertensives
C
Comparator
All antihypertensive drug products (single-pill or free combinations)
O
Outcome
Time course of dispensed packages of antihypertensive drugs between January 2016 and December 2020
Main Result
Absolute Event Rate: 10.9% vs 15.4%
Despite the 2018 ESC/ESH guidelines recommending fixed-dose combinations for hypertension, their use in Germany declined from 15.4% in 2016 to 10.9% in 2020, indicating significant guideline inertia.
Limitations
- Analysis is based on dispensing data claimed at the expense of statutory health insurance funds, lacking direct clinical outcomes or actual patient adherence data.
Cite This Study
Mahfoud et al. (2022) conducted an observational in Hypertension (n=73,300,000). Fixed-dose combination antihypertensives vs. All antihypertensive drug products was evaluated on Proportion of fixed-dose combinations among all dispensed antihypertensives. Between 2016 and 2020, the proportion of fixed-dose combination products among all dispensed antihypertensives in Germany decreased from 15.4% to 10.9%, documenting underutilization of guideline recommendations.
Topics
View Full Paper
Ask AI
Bookmark
Share